Pregabalin use and overdose rates in Australia have declined
Media coverage and new restrictions are linked to lower rates of drug dispensing and overdose calls.
Pregabalin use and overdose in Australia have declined in recent years. Major decreases in trends matched media coverage in December 2018 and prescribing and dispensing restrictions in May 2020.
The study used Pharmaceutical Benefits Scheme (PBS) data and overdose calls from 2016-24. The PBS data is a 10% random sample of people with drug subsidies. Overdose calls include self-harm, recreational use, and misuse.
Researchers found three breakpoints in dispensing data. These occurred in December 2018, May 2020, and December 2021. All breakpoints were associated with declines in overdose rates.
A latent class analysis of 57 744 people dispensed pregabalin in the 12 months after the final breakpoint found four groups. Latent class analysis is a way to find different groups of people.
A high risk group of 7 790 people, or 13.5%, was identified. This group was more likely to be male and younger. They were also more likely to use opioids and benzodiazepines.
These findings suggest that regulatory and risk communication measures may contribute to reducing pregabalin related harm.
Key facts
- Pregabalin use peaked in 2018 before plateauing and declining.
- The combined rate ratio for dispensing was 0.748.
- The combined rate ratio for overdose was 0.532.
- Approximately 118 390 fewer pregabalin prescriptions were recorded nationally by December 2021.